Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Lung Cancer. 2015 Mar 1;88(2):131–138. doi: 10.1016/j.lungcan.2015.02.017

Fig. 2.

Fig. 2

Re-expression of LKB1 in EKVX leads to resistance to paclitaxel. (A) EKVX isogenic cell lines were treated with 80nM paclitaxel for 48hrs then subjected to Annexin V-7AAD flow cytometry analysis. (B) EKVX isogenic cells were treated with varying doses (0, 10, 20, 40nM) of paclitaxel for 48hrs, and cell lysates were analyzed by immunoblot for apoptosis bio-markers caspase-3 and PARP. (C) Cell cycle analysis of the EKVX isogenic cells treated with 50nM paclitaxel for 24hrs. All experiments described in this figure were repeated three times.